Nanosized Drug Delivery Vectors and the Reticuloendothelial System

Kaminskas, Lisa M.; Boyd, Ben J.

doi:10.1007/978-94-007-1248-5_6

Cited by 7 publications

(3 citation statements)

References 43 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The uptake of radiolabeled GVs in non-target tissues is not surprisingly due to resident mature macrophages located close to the vesselwalls [38], removing [ 99m Tc]GVs from blood circulation rapidly. Furthermore, uptake and retention in the liver, spleen, and lungs is likely from Kupffer, red pulp macrophages, and reticular cells, respectively, present in these tissues.…”

Section: Discussionmentioning

confidence: 99%

In vivo Biodistribution of Radiolabeled Acoustic Protein Nanostructures

et al. 2017

View full text Add to dashboard Cite

Purpose Contrast-enhanced ultrasound plays an expanding role in oncology, but its applicability to molecular imaging is hindered by a lack of nanoscale contrast agents that can reach targets outside the vasculature. Gas vesicles (GVs)—a unique class of gas-filled protein nanostructures—have recently been introduced as a promising new class of ultrasound contrast agents that can potentially access the extravascular space and be modified for molecular targeting. The purpose of the present study is to determine the quantitative biodistribution of GVs, which is critical for their development as imaging agents. Procedures We use a novel bioorthogonal radiolabeling strategy to prepare technetium-99m-radiolabeled ([99mTc])GVs in high radiochemical purity. We use single photon emission computed tomography (SPECT) and tissue counting to quantitatively assess GV biodistribution in mice. Results Twenty minutes following administration to mice, the SPECT biodistribution shows that 84 % of [99mTc]GVs are taken up by the reticuloendothelial system (RES) and 13 % are found in the gall bladder and duodenum. Quantitative tissue counting shows that the uptake (mean ± SEM % of injected dose/organ) is 0.6 ± 0.2 for the gall bladder, 46.2 ± 3.1 for the liver, 1.91 ± 0.16 for the lungs, and 1.3 ± 0.3 for the spleen. Fluorescence imaging confirmed the presence of GVs in RES. Conclusions These results provide essential information for the development of GVs as targeted nanoscale imaging agents for ultrasound.

show abstract

Section: Discussionmentioning

confidence: 99%

In vivo Biodistribution of Radiolabeled Acoustic Protein Nanostructures

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A few studies have been dedicated to the attempts to limit the drug clearance, given that most administered NPs pool in the liver and spleen and are removed by the reticuloendothelial system after the administration [ 191 ]. Interestingly, NPs are flexible and can escape opsonization by the macrophages if coated with extra surface layers, such as PEG [ 192 ].…”

Section: Potential Of Nanoparticles In Drug Deliverymentioning

confidence: 99%

Nanoparticles for the treatment of glaucoma-associated neuroinflammation

et al. 2022

View full text Add to dashboard Cite

Recently, a considerable amount of literature has emerged around the theme of neuroinflammation linked to neurodegeneration. Glaucoma is a neurodegenerative disease characterized by visual impairment. Understanding the complex neuroinflammatory processes underlying retinal ganglion cell loss has the potential to improve conventional therapeutic approaches in glaucoma. Due to the presence of multiple barriers that a systemically administered drug has to cross to reach the intraocular space, ocular drug delivery has always been a challenge. Nowadays, studies are focused on improving the current therapies for glaucoma by utilizing nanoparticles as the modes of drug transport across the ocular anatomical and physiological barriers. This review offers some important insights on the therapeutic advancements made in this direction, focusing on the use of nanoparticles loaded with anti-inflammatory and neuroprotective agents in the treatment of glaucoma. The prospect of these novel therapies is discussed in relation to the current therapies to alleviate inflammation in glaucoma, which are being reviewed as well, along with the detailed molecular and cellular mechanisms governing the onset and the progression of the disease.

show abstract

“…Hydrophobic particles in the body are preferentially coated by plasma proteins (e.g., immunoglobulin, complement, albumin) and then cleared by the reticuloendothelial system (61). Thus, most particulate-based systems have relied on hydrophilic coatings or modifications to reduce this passive mechanism of adsorption and clearance.…”

Section: Effects Of Biomaterials On Immune Cells and Immunomodulamentioning

confidence: 99%

Biomaterial Strategies for Immunomodulation

Hotaling

Tang²,

Irvine³

et al. 2015

Annu. Rev. Biomed. Eng.

146

130

View full text Add to dashboard Cite

Strategies to enhance, suppress, or qualitatively shape the immune response are of importance for diverse biomedical applications, such as the development of new vaccines, treatments for autoimmune diseases and allergies, strategies for regenerative medicine, and immunotherapies for cancer. However, the intricate cellular and molecular signals regulating the immune system are major hurdles to predictably manipulating the immune response and developing safe and effective therapies. To meet this challenge, biomaterials are being developed that control how, where, and when immune cells are stimulated in vivo, and that can finely control their differentiation in vitro. We review recent advances in the field of biomaterials for immunomodulation, focusing particularly on designing biomaterials to provide controlled immunostimulation, targeting drugs and vaccines to lymphoid organs, and serving as scaffolds to organize immune cells and emulate lymphoid tissues. These ongoing efforts highlight the many ways in which biomaterials can be brought to bear to engineer the immune system.

show abstract

Nanosized Drug Delivery Vectors and the Reticuloendothelial System

Cited by 7 publications

References 43 publications

In vivo Biodistribution of Radiolabeled Acoustic Protein Nanostructures

In vivo Biodistribution of Radiolabeled Acoustic Protein Nanostructures

Nanoparticles for the treatment of glaucoma-associated neuroinflammation

Biomaterial Strategies for Immunomodulation

Contact Info

Product

Resources

About